ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Teva, Xenon Announce Phase II Study of Topical TV-45070 Did Not Meet Primary Endpoint
June 28, 2017Teva Pharmaceutical and Xenon Pharmaceuticals announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neuralgia (PHN) did not meet the primary endpoint of a statistically significant change in pain from baseline to -
Teva and Active Biotech Announce Concerto Trial of Laquinimod did not Meet Primary Endpoint
May 09, 2017Teva Pharmaceutical Industries and Active Biotech announced results from the Concerto trial in patients with relapsing-remitting multiple sclerosis (RRMS).
Pharma Sources Insight January 2025
